The Effect of Vitamin D Repletion on Kidney Stone Risk

Sponsor
Brown University (Other)
Overall Status
Terminated
CT.gov ID
NCT02752841
Collaborator
(none)
20
1
37

Study Details

Study Description

Brief Summary

Examine the effect of nutritional vitamin D repletion on urinary calcium excretion and kidney stone burden in calcium kidney stone formers

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Nutritional vitamin D repletion and maintenance
N/A

Detailed Description

The investigators plan to conduct a clinic-based interventional study of 50 patients followed at Miriam Hospital Kidney Stone Clinic with history of nephrolithiasis, urinary calcium excretion between 150 and 400 mg/day, and 25-vitamin D deficiency/insufficiency (defined as serum level ≤ 30ng/ml). The intervention is oral ergocalciferol 50,000 IU per week for 12 weeks (repletion course). After that, the same repletion course will be repeated if serum 25-vitamin D remains ≤ 30ng/ml or drops to ≤ 30ng/ml anytime during the study. Otherwise, a maintenance dose of cholecalciferol 1,000 IU daily or ergocalciferol 50,000 IU monthly will be prescribed for the rest of the study. Each participant will serve as his own control. The outcome is the change in urinary calcium excretion and stone burden assessed by renal ultrasound. The planned study duration is 12 months. The investigators will have greater than 95% power to detect a 10% increase in 24-hour urinary calcium.

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effect of Vitamin D Repletion on Urinary Calcium Excretion in Kidney Stone Formers With Vitamin D Deficiency and High Urinary Calcium
Actual Study Start Date :
May 1, 2016
Actual Primary Completion Date :
May 31, 2019
Actual Study Completion Date :
May 31, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Nutritional vitamin D repletion and maintenance

Dietary Supplement: Nutritional vitamin D repletion and maintenance
Ergocalciferol (50,000 IU weekly for 12 weeks) for vitamin D repletion, ergocalciferol (50,000 IU monthly) or cholecalciferol (1000 IU daily) for maintenance of vitamin D

Outcome Measures

Primary Outcome Measures

  1. Changes in urinary calcium excretion measured by timed urine collection [Baseline and 12 months]

    Examine changes in urine calcium excretion at the end of the 12month study. Urinary calcium excretion are measured by 24-hour urine collections for calcium (mg per day), and the differences are the changes of 24-hour urine calcium (mg per day) between those measured at month 12 and at the enrollment

Secondary Outcome Measures

  1. Changes in kidney stone burden measured by ultrasound [Baseline and 12 months]

    Changes in kidney stone burden at the end of the 12month study. Total stone burden is calculated by number of stones x stone sizes, i.e., patient A has one stone measured at 2 mm and two stones measured at 3 mm, then total stone burden = 1x2 +2x3=8mm.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • History of nephrolithiasis

  • 25(OH)D deficiency (defined as serum level ≤ 30ng/ml) within 3 months of enrollment

  • 24-hour urinary calcium excretion > 150 mg/day and < 400 mg/day (measured less than 2 months prior to study enrollment)

Exclusion Criteria:
  • Known uric acid, cystine, or struvite stone disease

  • Hypercalcemia (serum calcium >10.4 mg/dl within the past 12 months)

  • Gross hematuria within the past 6 months

  • Acute stone event within the past 1 month

  • Recent stone intervention within the past 1 month

  • Suspected or known secondary causes of hypercalciuria such as primary hyperparathyroidism, sarcoidosis, hyperthyroidism, or malignancy (except non-melanoma skin cancer)

  • Addition or dose change of medicines potentially affecting urinary calcium since enrollment 24-hour urine collection (including diuretics, magnesium supplements, potassium supplements, potassium citrate, and vitamin D supplementation)

  • Pregnancy

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Brown University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jie Tang, Associate Professor, Brown University
ClinicalTrials.gov Identifier:
NCT02752841
Other Study ID Numbers:
  • 879658-1
First Posted:
Apr 27, 2016
Last Update Posted:
Jul 23, 2019
Last Verified:
Jul 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 23, 2019